Teva Pharmaceutical Industries Ltd (TEVA) - Net Assets

Latest as of March 2026: ILA8.31 Billion ILA ≈ $22.28 Million USD

Based on the latest financial reports, Teva Pharmaceutical Industries Ltd (TEVA) has net assets worth ILA8.31 Billion ILA (≈ $22.28 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA40.43 Billion ≈ $108.38 Million USD) and total liabilities (ILA32.11 Billion ≈ $86.10 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how tangible is Teva Pharmaceutical Industries Ltd's equity to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	ILA8.31 Billion
% of Total Assets	20.56%
Annual Growth Rate	13.5%
5-Year Change	-29.6%
10-Year Change	-77.38%
Growth Volatility	27.66

Teva Pharmaceutical Industries Ltd - Net Assets Trend (1985–2025)

This chart illustrates how Teva Pharmaceutical Industries Ltd's net assets have evolved over time, based on quarterly financial data. See Teva Pharmaceutical Industries Ltd defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Teva Pharmaceutical Industries Ltd (1985–2025)

The table below shows the annual net assets of Teva Pharmaceutical Industries Ltd from 1985 to 2025. For live valuation and market cap data, see Teva Pharmaceutical Industries Ltd (TEVA) total market value.

Year	Net Assets	Change
2025-12-31	ILA7.92 Billion ≈ $21.22 Million	+38.39%
2024-12-31	ILA5.72 Billion ≈ $15.34 Million	-29.61%
2023-12-31	ILA8.13 Billion ≈ $21.79 Million	-6.50%
2022-12-31	ILA8.69 Billion ≈ $23.30 Million	-22.71%
2021-12-31	ILA11.24 Billion ≈ $30.14 Million	+1.65%
2020-12-31	ILA11.06 Billion ≈ $29.65 Million	-26.57%
2019-12-31	ILA15.06 Billion ≈ $40.38 Million	-4.63%
2018-12-31	ILA15.79 Billion ≈ $42.34 Million	-15.74%
2017-12-31	ILA18.75 Billion ≈ $50.25 Million	-46.43%
2016-12-31	ILA34.99 Billion ≈ $93.82 Million	+16.93%
2015-12-31	ILA29.93 Billion ≈ $80.23 Million	+28.14%
2014-12-31	ILA23.36 Billion ≈ $62.61 Million	+3.18%
2013-12-31	ILA22.64 Billion ≈ $60.69 Million	-1.01%
2012-12-31	ILA22.87 Billion ≈ $61.31 Million	+2.35%
2011-12-31	ILA22.34 Billion ≈ $59.90 Million	+1.55%
2010-12-31	ILA22.00 Billion ≈ $58.99 Million	+14.24%
2009-12-31	ILA19.26 Billion ≈ $51.63 Million	+17.72%
2008-12-31	ILA16.36 Billion ≈ $43.86 Million	+18.90%
2007-12-31	ILA13.76 Billion ≈ $36.89 Million	+23.11%
2006-12-31	ILA11.18 Billion ≈ $29.97 Million	+84.73%
2005-12-31	ILA6.05 Billion ≈ $16.22 Million	+12.05%
2004-12-31	ILA5.40 Billion ≈ $14.48 Million	+63.82%
2003-12-31	ILA3.30 Billion ≈ $8.84 Million	+79.69%
2002-12-31	ILA1.83 Billion ≈ $4.92 Million	+32.65%
2001-12-31	ILA1.38 Billion ≈ $3.71 Million	+19.94%
2000-12-31	ILA1.15 Billion ≈ $3.09 Million	+55.33%
1999-12-31	ILA742.30 Million ≈ $1.99 Million	+12.54%
1998-12-31	ILA659.60 Million ≈ $1.77 Million	+7.64%
1997-12-31	ILA612.80 Million ≈ $1.64 Million	+14.50%
1996-12-31	ILA535.20 Million ≈ $1.43 Million	+31.31%
1995-12-31	ILA407.60 Million ≈ $1.09 Million	+19.04%
1994-12-31	ILA342.40 Million ≈ $917.96K	+27.81%
1993-12-31	ILA267.90 Million ≈ $718.23K	+20.08%
1992-12-31	ILA223.10 Million ≈ $598.12K	+21.91%
1991-12-31	ILA183.00 Million ≈ $490.62K	+34.96%
1990-12-31	ILA135.60 Million ≈ $363.54K	+13.57%
1989-12-31	ILA119.40 Million ≈ $320.11K	+20.48%
1988-12-31	ILA99.10 Million ≈ $265.68K	+71.45%
1986-12-31	ILA57.80 Million ≈ $154.96K	+15.83%
1985-12-31	ILA49.90 Million ≈ $133.78K	--

Equity Component Analysis

This analysis shows how different components contribute to Teva Pharmaceutical Industries Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 58413.6% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Common Stock	ILA58.00 Million	0.73%
Other Comprehensive Income	ILA-2.39 Billion	-30.22%
Other Components	ILA24.01 Billion	303.43%
Total Equity	ILA7.91 Billion	100.00%

Teva Pharmaceutical Industries Ltd Competitors by Market Cap

The table below lists competitors of Teva Pharmaceutical Industries Ltd ranked by their market capitalization.

Company	Market Cap
PT Daya Intiguna Yasa Tbk JK:MDIY	$1.23 Billion
IDT Corporation NYSE:IDT	$1.23 Billion
Wealthfront Corporation Common Stock NASDAQ:WLTH	$1.23 Billion
Adriatic Metals Plc F:3FN	$1.23 Billion
Manchester United Ltd NYSE:MANU	$1.23 Billion
Growthpoint Properties Australia AU:GOZ	$1.23 Billion
Hangjin Technology Co Ltd SHE:000818	$1.23 Billion
BioGaia AB (publ) ST:BIOG-B	$1.23 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Teva Pharmaceutical Industries Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 5,373,000,000 to 7,911,642,000, a change of 2,538,642,000 (47.2%).
Net income of 1,527,366,000 contributed positively to equity growth.
Other comprehensive income increased equity by 757,000,000.
Other factors increased equity by 254,276,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	ILA1.53 Billion	+19.31%
Other Comprehensive Income	ILA757.00 Million	+9.57%
Other Changes	ILA254.28 Million	+3.21%
Total Change	ILA-	47.25%

Book Value vs Market Value Analysis

This analysis compares Teva Pharmaceutical Industries Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1378.70x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 82120.19x to 1378.70x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
1985-12-31	ILA0.11	ILA9379.00	x
1986-12-31	ILA0.13	ILA9379.00	x
1988-12-31	ILA0.29	ILA9379.00	x
1989-12-31	ILA0.35	ILA9379.00	x
1990-12-31	ILA0.34	ILA9379.00	x
1991-12-31	ILA0.44	ILA9379.00	x
1992-12-31	ILA0.54	ILA9379.00	x
1993-12-31	ILA0.63	ILA9379.00	x
1994-12-31	ILA0.71	ILA9379.00	x
1995-12-31	ILA0.83	ILA9379.00	x
1996-12-31	ILA1.09	ILA9379.00	x
1997-12-31	ILA1.25	ILA9379.00	x
1998-12-31	ILA1.35	ILA9379.00	x
1999-12-31	ILA1.51	ILA9379.00	x
2000-12-31	ILA2.21	ILA9379.00	x
2001-12-31	ILA2.53	ILA9379.00	x
2002-12-31	ILA3.26	ILA9379.00	x
2003-12-31	ILA5.58	ILA9379.00	x
2004-12-31	ILA7.83	ILA9379.00	x
2005-12-31	ILA8.87	ILA9379.00	x
2006-12-31	ILA13.84	ILA9379.00	x
2007-12-31	ILA16.53	ILA9379.00	x
2008-12-31	ILA19.88	ILA9379.00	x
2009-12-31	ILA21.45	ILA9379.00	x
2010-12-31	ILA23.83	ILA9379.00	x
2011-12-31	ILA24.85	ILA9379.00	x
2012-12-31	ILA26.08	ILA9379.00	x
2013-12-31	ILA26.55	ILA9379.00	x
2014-12-31	ILA27.17	ILA9379.00	x
2015-12-31	ILA34.45	ILA9379.00	x
2016-12-31	ILA34.69	ILA9379.00	x
2017-12-31	ILA17.09	ILA9379.00	x
2018-12-31	ILA14.40	ILA9379.00	x
2019-12-31	ILA12.81	ILA9379.00	x
2020-12-31	ILA9.16	ILA9379.00	x
2021-12-31	ILA9.28	ILA9379.00	x
2022-12-31	ILA7.11	ILA9379.00	x
2023-12-31	ILA6.71	ILA9379.00	x
2024-12-31	ILA4.75	ILA9379.00	x
2025-12-31	ILA6.80	ILA9379.00	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Teva Pharmaceutical Industries Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 19.31%
The company demonstrates strong efficiency in generating profits from shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 8.18%
• Asset Turnover: 0.46x
• Equity Multiplier: 5.15x
Recent ROE (19.31%) is above the historical average (5.61%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
1985	15.23%	8.33%	0.66x	2.79x	ILA2.61 Million
1986	25.61%	10.60%	0.98x	2.47x	ILA9.02 Million
1988	12.11%	5.68%	0.85x	2.50x	ILA2.09 Million
1989	14.15%	6.01%	0.98x	2.40x	ILA4.96 Million
1990	15.34%	6.32%	0.96x	2.54x	ILA7.24 Million
1991	12.99%	7.25%	0.87x	2.07x	ILA5.46 Million
1992	14.66%	8.02%	0.91x	2.00x	ILA10.37 Million
1993	21.50%	11.45%	0.89x	2.10x	ILA30.75 Million
1994	20.94%	12.18%	0.87x	1.98x	ILA37.40 Million
1995	19.81%	11.95%	0.77x	2.16x	ILA39.51 Million
1996	13.74%	7.70%	0.77x	2.32x	ILA19.98 Million
1997	16.58%	9.09%	0.94x	1.94x	ILA40.30 Million
1998	10.44%	6.17%	0.78x	2.18x	ILA2.92 Million
1999	15.87%	9.19%	0.75x	2.31x	ILA43.60 Million
2000	12.89%	8.48%	0.61x	2.48x	ILA33.28 Million
2001	20.15%	13.39%	0.60x	2.51x	ILA140.14 Million
2002	22.43%	16.29%	0.54x	2.53x	ILA227.36 Million
2003	21.01%	21.09%	0.55x	1.80x	ILA362.06 Million
2004	6.16%	6.91%	0.50x	1.79x	ILA-207.09 Million
2005	17.75%	20.42%	0.51x	1.72x	ILA468.07 Million
2006	4.90%	6.49%	0.41x	1.84x	ILA-568.20 Million
2007	14.22%	20.75%	0.40x	1.71x	ILA579.60 Million
2008	3.90%	5.73%	0.34x	2.02x	ILA-995.00 Million
2009	10.40%	14.39%	0.41x	1.76x	ILA77.80 Million
2010	15.18%	20.66%	0.41x	1.78x	ILA1.14 Billion
2011	12.43%	15.07%	0.37x	2.26x	ILA539.50 Million
2012	8.62%	9.66%	0.40x	2.22x	ILA-313.80 Million
2013	5.62%	6.25%	0.43x	2.11x	ILA-987.50 Million
2014	13.10%	15.07%	0.44x	1.99x	ILA723.70 Million
2015	5.33%	8.08%	0.36x	1.82x	ILA-1.39 Billion
2016	0.99%	1.50%	0.24x	2.79x	ILA-3.00 Billion
2017	-93.70%	-72.66%	0.32x	4.07x	ILA-18.00 Billion
2018	-14.62%	-11.40%	0.31x	4.13x	ILA-3.62 Billion
2019	-7.15%	-5.92%	0.29x	4.11x	ILA-2.40 Billion
2020	-39.80%	-23.95%	0.33x	5.05x	ILA-4.99 Billion
2021	4.06%	2.63%	0.33x	4.64x	ILA-610.80 Million
2022	-29.80%	-15.77%	0.34x	5.57x	ILA-3.14 Billion
2023	-7.45%	-3.53%	0.36x	5.79x	ILA-1.31 Billion
2024	-30.50%	-9.91%	0.42x	7.32x	ILA-2.18 Billion
2025	19.31%	8.18%	0.46x	5.15x	ILA736.20 Million

Industry Comparison

This section compares Teva Pharmaceutical Industries Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $3,782,115,907
Average return on equity (ROE) among peers: -172.65%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Teva Pharmaceutical Industries Ltd (TEVA)	ILA8.31 Billion	15.23%	3.86x	$1.23 Billion
Canzon Israel Ltd (CNZN)	$12.27 Million	-25.33%	0.07x	$1.71 Million
Intercure (INCR)	$396.36 Million	-9.01%	0.74x	$45.45 Million
Intelicanna Ltd (INTL)	$33.29 Billion	2.45%	0.22x	$8.66 Million
Kamada (KMDA)	$22.67 Million	-15.40%	2.77x	$327.69 Million
Nextage Therapeutics Ltd (NXTG)	$516.00K	-1497.67%	7.28x	$5.79 Million
Rekah Pharmaceutical Industry Ltd (REKA)	$123.66 Million	-3.57%	1.62x	$32.62 Million
Seach Medical Group Ltd (SEMG)	$95.58 Million	5.60%	0.34x	$22.00 Million
Together Startup Network Ltd (TGTR)	$-187.00K	0.00%	0.00x	$8.50 Million
Tikun Olam Cannbit Pharmaceuticals Ltd (TKUN)	$99.87 Million	-10.90%	0.56x	$28.21 Million

About Teva Pharmaceutical Industries Ltd

TA:TEVA Israel Drug Manufacturers - Specialty & Generic

Market Cap

$29.28 Billion

ILA10.92 Trillion ILA

Market Cap Rank

#8171 Global

#68 in Israel

Share Price

ILA9379.00

Change (1 day)

-0.56%

52-Week Range

ILA5374.00 - ILA11350.00

All Time High

ILA25447.60